Clinical Trial Update: Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting [NA]

View source ↗

Summary

Clinical trial update on reduced exposure study with THS 2.2 Menthol in confinement and ambulatory settings; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoking-related Disease

Drugs mentioned

• THS 2.2 Menthol (null)

Snippet

Sponsor: Philip Morris Products S.A. | Conditions: Smoking | NA | Status: COMPLETED | Results posted: 2017-04-05